Solventum Corporation (SOLV) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $76.39 (-0.67%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 26, 2026 | Brett Fishbin | KeyBanc | $97.00 | +27.0% |
| Dec 2, 2025 | Ryan Zimmerman | BTIG | $100.00 | +30.9% |
| Oct 1, 2025 | Kevin Caliendo | UBS | $77.00 | +0.8% |
| Jul 15, 2025 | Patrick Wood | Morgan Stanley | $103.00 | +34.8% |
| Dec 3, 2024 | Steven Valiquette | Mizuho Securities | $70.00 | -8.4% |
| Oct 7, 2024 | Rick Wise | Stifel Nicolaus | $82.00 | +7.4% |
| Oct 7, 2024 | Jason Bednar | Piper Sandler | $71.00 | -7.0% |
| Jul 15, 2024 | Patrick Wood | Morgan Stanley | $55.00 | -28.0% |
| May 30, 2024 | David Roman | Goldman Sachs | $54.00 | -29.3% |
| Apr 9, 2024 | Patrick Wood | Morgan Stanley | $70.00 | -8.4% |
| Apr 8, 2024 | Vik Chopra | Wells Fargo | $69.00 | -9.7% |
Top Analysts Covering SOLV
SOLV vs Sector & Market
| Metric | SOLV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.23 | 2.24 | 2.41 |
| Analyst Count | 13 | 8 | 19 |
| Target Upside | +7.4% | +11475.0% | +17.1% |
| P/E Ratio | 9.46 | 4.02 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.75B | $8.16B | $8.36B | 9 |
| 2027-03-31 | $2.03B | $2.05B | $2.07B | 2 |
| 2027-06-30 | $2.10B | $2.12B | $2.15B | 2 |
| 2027-09-30 | $2.10B | $2.12B | $2.15B | 2 |
| 2027-12-31 | $2.14B | $2.16B | $2.19B | 2 |
| 2028-03-31 | $2.11B | $2.13B | $2.16B | 1 |
| 2028-06-30 | $2.18B | $2.21B | $2.23B | 1 |
| 2028-09-30 | $2.19B | $2.21B | $2.23B | 1 |
| 2028-12-31 | $2.22B | $2.25B | $2.27B | 1 |
| 2029-12-31 | $8.47B | $8.95B | $9.11B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6.23 | $6.47 | $6.53 | 8 |
| 2027-03-31 | $1.57 | $1.59 | $1.62 | 2 |
| 2027-06-30 | $1.79 | $1.82 | $1.84 | 2 |
| 2027-09-30 | $1.82 | $1.85 | $1.87 | 2 |
| 2027-12-31 | $1.90 | $1.93 | $1.96 | 2 |
| 2028-03-31 | $1.66 | $1.69 | $1.71 | 3 |
| 2028-06-30 | $1.92 | $1.95 | $1.98 | 3 |
| 2028-09-30 | $1.95 | $1.97 | $2.00 | 3 |
| 2028-12-31 | $2.03 | $2.05 | $2.08 | 3 |
| 2029-12-31 | $7.26 | $7.81 | $8.00 | 2 |
Frequently Asked Questions
What is the analyst consensus for SOLV?
The consensus among 13 analysts covering Solventum Corporation (SOLV) is Buy with an average price target of $100.50.
What is the highest price target for SOLV?
The highest price target for SOLV is $103.00, set by Patrick Wood at Morgan Stanley on 2025-07-15.
What is the lowest price target for SOLV?
The lowest price target for SOLV is $54.00, set by David Roman at Goldman Sachs on 2024-05-30.
How many analysts cover SOLV?
13 analysts have issued ratings for Solventum Corporation in the past 12 months.
Is SOLV a buy or sell right now?
Based on 13 analyst ratings, SOLV has a consensus rating of Buy (2.23/5) with a +7.4% upside to the consensus target of $100.50.
What are the earnings estimates for SOLV?
Analysts estimate SOLV will report EPS of $6.47 for the period ending 2026-12-31, with revenue estimated at $8.16B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.